The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 21, 2017

Filed:

Apr. 06, 2015
Applicants:

President and Fellows of Harvard College, Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Kenneth C. Anderson, Wellesley, MA (US);

James E. Bradner, Weston, MA (US);

Edward Franklin Greenberg, Cleveland, OH (US);

Teru Hideshima, Brookline, MA (US);

Nicholas Paul Kwiatkowski, Auburn, MA (US);

Ralph Mazitschek, Belmont, MA (US);

Stuart L. Schreiber, Boston, MA (US);

Jared Shaw, Davis, CA (US);

Stephen J. Haggarty, Gloucester, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/05 (2006.01); A61K 31/35 (2006.01); A61K 31/357 (2006.01); A61K 31/4965 (2006.01); A61K 31/69 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); G01N 33/50 (2006.01); A61K 38/50 (2006.01); A61K 31/422 (2006.01);
U.S. Cl.
CPC ...
A61K 38/05 (2013.01); A61K 31/35 (2013.01); A61K 31/357 (2013.01); A61K 31/422 (2013.01); A61K 31/4965 (2013.01); A61K 31/69 (2013.01); A61K 38/50 (2013.01); A61K 45/06 (2013.01); A61K 49/0008 (2013.01); G01N 33/5011 (2013.01);
Abstract

The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.


Find Patent Forward Citations

Loading…